Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2000-03-22
2008-09-30
Kemmerer, Elizabeth C. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387900, C530S388100, C530S388150, C530S387100, C530S389100, C424S130100, C424S133100, C424S134100, C424S139100, C424S141100, C424S142100, C424S143100, C435S069100, C435S069700, C435S070210
Reexamination Certificate
active
07429646
ABSTRACT:
The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4444887 (1984-04-01), Hoffmann
patent: 4474893 (1984-10-01), Reading
patent: 4714681 (1987-12-01), Reading
patent: 4716111 (1987-12-01), Osband et al.
patent: 4925648 (1990-05-01), Hansen et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4946788 (1990-08-01), Delespesse
patent: 5112946 (1992-05-01), Maione
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5258498 (1993-11-01), Huston et al.
patent: 5310662 (1994-05-01), Evans et al.
patent: 5314995 (1994-05-01), Fell, Jr. et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5349052 (1994-09-01), Delgado et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5359039 (1994-10-01), Smith et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5413923 (1995-05-01), Kucherlapati et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5464938 (1995-11-01), Smith et al.
patent: 5474981 (1995-12-01), Leder et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5573920 (1996-11-01), Randle
patent: 5580717 (1996-12-01), Dower et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5612460 (1997-03-01), Zalipsky
patent: 5622929 (1997-04-01), Willner et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5698426 (1997-12-01), Huse
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750753 (1998-05-01), Kimae et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5811097 (1998-09-01), Allison et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 2045869 (1991-12-01), None
patent: 2260754 (1998-01-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 282 317 (1988-09-01), None
patent: 0 307 434 (1989-03-01), None
patent: 0 367 166 (1990-05-01), None
patent: 0 393 438 (1990-10-01), None
patent: 0 396 387 (1990-11-01), None
patent: 0 399 816 (1990-11-01), None
patent: 0 401 384 (1990-12-01), None
patent: 0 506 477 (1992-09-01), None
patent: 0 519 596 (1992-12-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 585 939 (1994-03-01), None
patent: 0 592 106 (1994-04-01), None
patent: 0 682 110 (1995-11-01), None
patent: WO 89/01036 (1989-02-01), None
patent: WO 89/12624 (1989-12-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 91/06570 (1991-05-01), None
patent: WO 91/09045 (1991-06-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 91/14438 (1991-10-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO 92/06194 (1992-04-01), None
patent: WO 92/08495 (1992-05-01), None
patent: WO 92/08802 (1992-05-01), None
patent: WO 92/22324 (1992-12-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/20219 (1993-10-01), None
patent: WO 93/21232 (1993-10-01), None
patent: WO 94/09137 (1994-04-01), None
patent: WO 94/13808 (1994-06-01), None
patent: WO 95/06058 (1995-03-01), None
patent: WO 95/15982 (1995-06-01), None
patent: WO 95/20401 (1995-08-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 96/14328 (1996-05-01), None
patent: WO 96/26736 (1996-09-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34095 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 96/39515 (1996-12-01), None
patent: WO 96/40281 (1996-12-01), None
patent: WO 97/04658 (1997-02-01), None
patent: WO 97/06251 (1997-02-01), None
patent: WO 97/33904 (1997-09-01), None
patent: WO 97/34911 (1997-09-01), None
patent: WO 98/02543 (1998-01-01), None
patent: WO 98/06842 (1998-02-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 98/07880 (1998-02-01), None
patent: WO 98/16654 (1998-04-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/25967 (1998-06-01), None
patent: WO 98/30693 (1998-07-01), None
patent: WO 98/30694 (1998-07-01), None
patent: WO 98/31799 (1998-07-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46645 (1998-10-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 98/51346 (1998-11-01), None
patent: WO 98/54202 (1998-12-01), None
patent: WO 98/56892 (1998-12-01), None
US 5,843,791, 12/1998, Hauptmann et al. (withdrawn)
Montgomery RI et al. Cell 1996, vol. 87, pp. 427-436. Herpes Simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF Receptor family.
Sandhu JS. Critical Rev Biotechnol. 1992, vol. 12, pp. 437-462. Protein engineering of Antibodies.
Ji TH, Grossman M, and Ji I. 1998, J Biol Chem, vol. 273, pp. 17299-17302. G rpotein coupled receptors.
Skolnick J and Fetrow JS. 2000, Trends in Bitech., vol. 18, pp. 34-39. from genes to protein strucutre and function: novel applications of computtional apporaches in the genomic era.
Murdoch C and Finn A, 2000, Blooc, vol. 95, pp. 3032-3043. Chemokine rceptors and their role in inflammation and infectious diseases.
Bork P., 2000, Genome research, vol. 10, pp. 390-400. Pwers and pitfalls in sequence analysis: the 70% hurdle.
Harrop, J.A. et al., “Herpesvirus Entry Mediator Ligand (HVEM-L), a Novel Ligand for HVEM/TR2, Stimulates Proliferation of T Cells and Inhibits HT29 Cell Growth,”J. Biol. Chem. 273:27548-27556 (Oct. 1998).
Førre, Ø. et al., “New treatment possibilities in rheumatoid arthritis,”Scand. J. Rheumatol. 29:73-84, Scandinavian University Press (2000).
Keystone, E.C., “The Role of Tumor Necrosis Factor Antagonism in Clinical Practice,”J. Rheumatol. 26(Suppl. 57):22-28, The Journal of Rheumatology Publishing Company Ltd. (May 1999).
Wallace, C.A. et al., “Predicting Remission in Juvenile Rheumatoid Arthritis with Methotrexate Treatment,”J. Rheumatol. 20:118-122, The Journal of Rheumatology Publishing Company Ltd. (1993).
Adams, M.D. et al., “Sequence identification of 2,375 human brain genes,”Nature 355:632-634 (1992).
Adams, M.D. et al., “Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project,”Science 252:1651-1656 (1991).
Aggarwal, B.B. and K. Watarajan, “Tumor necrosis factors: Developments during the last decade,”Eur. Cytokine Netw. 7(2):93-124 (Apr.-Jun. 1996).
Altschul, S.F. et al., “Basic Local Alignment Search Tool,”J. Mol. Biol. 215:403-410 (1990).
Ames, R. S., et al., “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins,”J. Immunol. Meth. 184:177-186 (Aug
Gentz Reiner L.
Ni Jian
Rosen Craig A.
Human Genome Sciences Inc.
Kemmerer Elizabeth C.
LandOfFree
Antibodies to human tumor necrosis factor receptor-like 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to human tumor necrosis factor receptor-like 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to human tumor necrosis factor receptor-like 2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981757